Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Heart disease is the leading cause of death worldwide and its prevalence is growing. It is estimated that by 2030, 44% of the US population is projected to have some form of cardiovascular disease, which encompasses heart conditions and stroke. Over the same time period, the total direct medical costs are expected to nearly triple.1
Physicians may perform nuclear medicine tests—such as myocardial perfusion imaging—to diagnose heart disease and monitor a patient’s progress over time.
Jubilant DraxImage is committed to developing products and technologies that enable physicians to optimize the diagnosis and risk stratification of patients with heart disease. Jubilant DraxImage is making significant investments in nuclear cardiology to help realize its promise for healthcare professionals, patients, and the entire healthcare system.